These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 38187104)
21. Detection of Axillary Lymph Node Involvement in Early-Stage Breast Cancer: Comparison between Staging Gupta R; Das J; Sinha S; Agarwal S; Sharma A; Ahmed R; Chanda A; Arun I; Ray S Indian J Nucl Med; 2023; 38(3):249-254. PubMed ID: 38046972 [TBL] [Abstract][Full Text] [Related]
22. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases. Shao M; Zi J; Wen G J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884 [TBL] [Abstract][Full Text] [Related]
23. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497 [TBL] [Abstract][Full Text] [Related]
24. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT. Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353 [No Abstract] [Full Text] [Related]
25. Diagnostic Value of Axillary Ultrasound, MRI, and Aktaş A; Gürleyik MG; Aydın Aksu S; Aker F; Güngör S Eur J Breast Health; 2022 Jan; 18(1):37-47. PubMed ID: 35059590 [TBL] [Abstract][Full Text] [Related]
26. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668 [TBL] [Abstract][Full Text] [Related]
27. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer. Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071 [TBL] [Abstract][Full Text] [Related]
28. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients. Choi WH; Yoo IR; O JH; Kim SH; Chung SK Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574 [TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270 [TBL] [Abstract][Full Text] [Related]
30. Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer - a retrospective comparative study with PET/CT and breast MRI. Sae-Lim C; Wu WP; Chang MC; Lai HW; Chen ST; Chou CT; Liao CY; Huang HI; Chen ST; Chen DR; Hung CL World J Surg Oncol; 2024 Jan; 22(1):12. PubMed ID: 38183069 [TBL] [Abstract][Full Text] [Related]
31. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy. Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091 [TBL] [Abstract][Full Text] [Related]
32. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience. Kim J; Lee J; Chang E; Kim S; Suh K; Sul J; Song I; Kim Y; Lee C World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728 [TBL] [Abstract][Full Text] [Related]
33. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma. Ottenhof SR; Djajadiningrat RS; Versleijen MWJ; Donswijk ML; van der Noort V; Brouwer OR; Graafland NM; Vegt E; Horenblas S Eur Urol Focus; 2022 Jan; 8(1):98-104. PubMed ID: 33685842 [TBL] [Abstract][Full Text] [Related]
34. Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid de Mooij CM; Samiei S; Mitea C; Lobbes MBI; Kooreman LFS; Heuts EM; Beets-Tan RGH; van Nijnatten TJA; Smidt ML Clin Radiol; 2022 Oct; 77(10):e732-e740. PubMed ID: 35850866 [TBL] [Abstract][Full Text] [Related]
35. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
36. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522 [TBL] [Abstract][Full Text] [Related]
37. Role of FDG PET-CT in evaluation of locoregional nodal disease for initial staging of breast cancer. Liu Y World J Clin Oncol; 2014 Dec; 5(5):982-9. PubMed ID: 25493234 [TBL] [Abstract][Full Text] [Related]
38. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer. Fujii T; Yajima R; Tatsuki H; Kuwano H Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic Value of Voskuilen CS; Schweitzer D; Jensen JB; Nielsen AM; Joniau S; Muilwijk T; Necchi A; Azizi M; Spiess PE; Briganti A; Bandini M; Goffin K; Bouchelouche K; van Werkhoven E; Shariat SF; Xylinas E; Azawi NH; Ku JH; Foerster B; van Rhijn BWG; Vegt E; Hendricksen K Eur Urol Oncol; 2020 Feb; 3(1):73-79. PubMed ID: 31591037 [TBL] [Abstract][Full Text] [Related]
40. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]